Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and Sound Pharmaceuticals completed this new Phase 2a study testing SPI-1005, an investigational drug that contains ebselen, as a new treatment for bipolar disorder.

Trees in the shape of two heads, one with green leaves in blue sky and the other with empty branches in grey sky.

Professor Phil Cowen, Department of Psychiatry, University of Oxford, said,

“This work was done in collaboration with colleagues from the Department of Pharmacology at the University of Oxford who discovered that a drug called ebselen had pharmacological properties similar to those of the mood-stabilising drug, lithium. Lithium is a very useful agent in bipolar disorder but is not well-tolerated and requires regular blood tests. Ebselen would be free from these problems.

"The study shows important preliminary evidence of therapeutic activity for SPI-1005 in bipolar disorder. This pilot investigation has given us critical information to inform design of future trials and has confirmed the safety of SPI-1005 in a group of patients with severe mental illness taking multiple medications.” 

The study was funded by the Stanley Medical Research Institute and the medication was supplied by Sound Pharmaceuticals.

To read the full press release

To read the full study, A phase 2a randomised, double-blind, plcebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Kam Bhui joins MQ Science Council

Professor Kam Bhui appointed to MQ’s Science Council, a group of global experts who guide MQ’s research.

Ensuring LGBTQI+ people are treated fairly in mental health data

Andrey Kormilitzin outlines a new participatory study aimed at improving AI to take account of LGBTQI+ people so that their needs are better met by mental health services.

Friendship and mental health in adolescents

Tanya Manchanda's new paper investigates the role of friendship on the mental health outcomes of adolescents

Major wellbeing survey for 9-18 year olds launched

Researchers at Oxford are encouraging schools and colleges in four areas of the country to sign up to be part of the OxWell Student Survey.

‘Thinking Family’ when an adult has a serious illness

New research shows that although patient’s family details were often recorded, this information was not routinely used to help patients share their diagnosis with children.

Treating mental illness with electricity - new podcast

A new wave of treatments that stimulate the brain with electricity are showing promise on patients and in clinical trials.